Management Interviews | Latest & Breaking News on Management Interviews | Photos, Videos, Breaking Stories and Articles on Management Interviews

you are here: Home News

EXCLUSIVE: Kiran Mazumdar-Shaw asks govt to let companies use CSR funds to vaccinate employees
Biocon confident of meeting $200-million revenue guidance target for biologics segment
Mechanics of Modicare: The health scheme fine print
Biologics biz a large value unlocking opportunity; see revival from Q4: Biocon
Focus on growth, investments; capacity in Biologics a growth driver: Syngene Intl
Partnership with Sandoz is for the future wave of biosimilars: Biocon
TCS biggest wealth creator in 2012-17, Ajanta Pharma the fastest: Wealth Creation Study
Trastuzumab approval is a milestone: Biocon
EMA communication with regards to Trastuzumab does not mean an approval: Biocon
Optimistic about entry into generics market; hoping for better returns in H2: Biocon
It wouldn't be wise to change Biocon's EPS estimate with CRL received: Nirmal Bang
Profits from Copaxone generics to help strengthen balance sheet, expansion: Natco CEO
Expect Malaysian unit to contribute 3/4th of insulin biz revenue going ahead: Biocon
Biocon seeks withdrawal of application for two biosimilars under European drug regulator review
Will try & ask for re-inspection at the earliest, says Biocon
Countdown to GST: Find out how India Inc views its impacts
EXCLUSIVE: Biocon open to ‘unlocking value’ in units after 5 years; may look at M&A
To cut healthcare costs, US must partner India: Biocon's Shaw
Biocon to see inspections by USFDA & EMA in April-May: Sources
Biocon chief sees anti-cancer biosimilar launch in FY19
Biocon well-poised to be a frontrunner in biosimilars: MD
I don't see Trump's views affecting Indian drug cos: Biocon CMD
Speciality offers better returns, says Biocon Chief
Demonetisation has impacted Indian sales, not exports: Biocon
Half of US stunned, other half exhilarated with Trump win: Shaw

English

Markets

News

Personal Finance

Mutual Funds

Commodities

Media

Invest Now

Specials

EXCLUSIVE: Kiran Mazumdar-Shaw asks govt to let companies use CSR funds to vaccinate employees

Biocon confident of meeting $200-million revenue guidance target for biologics segment

Mechanics of Modicare: The health scheme fine print

Biologics biz a large value unlocking opportunity; see revival from Q4: Biocon

Focus on growth, investments; capacity in Biologics a growth driver: Syngene Intl

Partnership with Sandoz is for the future wave of biosimilars: Biocon

TCS biggest wealth creator in 2012-17, Ajanta Pharma the fastest: Wealth Creation Study

Trastuzumab approval is a milestone: Biocon

EMA communication with regards to Trastuzumab does not mean an approval: Biocon

Optimistic about entry into generics market; hoping for better returns in H2: Biocon

It wouldn't be wise to change Biocon's EPS estimate with CRL received: Nirmal Bang

Profits from Copaxone generics to help strengthen balance sheet, expansion: Natco CEO

Expect Malaysian unit to contribute 3/4th of insulin biz revenue going ahead: Biocon

Biocon seeks withdrawal of application for two biosimilars under European drug regulator review

Will try & ask for re-inspection at the earliest, says Biocon

Countdown to GST: Find out how India Inc views its impacts

EXCLUSIVE: Biocon open to ‘unlocking value’ in units after 5 years; may look at M&A

To cut healthcare costs, US must partner India: Biocon's Shaw

Biocon to see inspections by USFDA & EMA in April-May: Sources

Biocon chief sees anti-cancer biosimilar launch in FY19

Biocon well-poised to be a frontrunner in biosimilars: MD

I don't see Trump's views affecting Indian drug cos: Biocon CMD

Speciality offers better returns, says Biocon Chief

Demonetisation has impacted Indian sales, not exports: Biocon

Half of US stunned, other half exhilarated with Trump win: Shaw